JP5388858B2 - ニューロフィジンを使用する心機能不全の診断および危険性の層化 - Google Patents

ニューロフィジンを使用する心機能不全の診断および危険性の層化 Download PDF

Info

Publication number
JP5388858B2
JP5388858B2 JP2009539604A JP2009539604A JP5388858B2 JP 5388858 B2 JP5388858 B2 JP 5388858B2 JP 2009539604 A JP2009539604 A JP 2009539604A JP 2009539604 A JP2009539604 A JP 2009539604A JP 5388858 B2 JP5388858 B2 JP 5388858B2
Authority
JP
Japan
Prior art keywords
marker
dysfunction
cardiac dysfunction
cardiac
neurophysin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009539604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511877A (ja
JP2010511877A5 (enExample
Inventor
アンドレアス ベルクマン，
ヨアキム ストラック，
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベー．エル．アー．ハー．エム．エス ゲーエムベーハー filed Critical ベー．エル．アー．ハー．エム．エス ゲーエムベーハー
Publication of JP2010511877A publication Critical patent/JP2010511877A/ja
Publication of JP2010511877A5 publication Critical patent/JP2010511877A5/ja
Application granted granted Critical
Publication of JP5388858B2 publication Critical patent/JP5388858B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009539604A 2006-12-08 2007-12-10 ニューロフィジンを使用する心機能不全の診断および危険性の層化 Expired - Fee Related JP5388858B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006058266A DE102006058266A1 (de) 2006-12-08 2006-12-08 Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102006058266.7 2006-12-08
PCT/DE2007/002215 WO2008067806A2 (de) 2006-12-08 2007-12-10 Diagnose und risikostratifizierung von herzinsuffizienz mittels neurophysin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013117577A Division JP2013210385A (ja) 2006-12-08 2013-06-04 ニューロフィジンを使用する心機能不全の診断および危険性の層化

Publications (3)

Publication Number Publication Date
JP2010511877A JP2010511877A (ja) 2010-04-15
JP2010511877A5 JP2010511877A5 (enExample) 2011-11-24
JP5388858B2 true JP5388858B2 (ja) 2014-01-15

Family

ID=39363234

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009539604A Expired - Fee Related JP5388858B2 (ja) 2006-12-08 2007-12-10 ニューロフィジンを使用する心機能不全の診断および危険性の層化
JP2013117577A Pending JP2013210385A (ja) 2006-12-08 2013-06-04 ニューロフィジンを使用する心機能不全の診断および危険性の層化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013117577A Pending JP2013210385A (ja) 2006-12-08 2013-06-04 ニューロフィジンを使用する心機能不全の診断および危険性の層化

Country Status (6)

Country Link
US (1) US20100093012A1 (enExample)
EP (1) EP2100145B1 (enExample)
JP (2) JP5388858B2 (enExample)
CN (1) CN101583874B (enExample)
DE (1) DE102006058266A1 (enExample)
WO (1) WO2008067806A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5320294B2 (ja) 2006-10-26 2013-10-23 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化
US20110262939A1 (en) * 2008-10-31 2011-10-27 B.R.A.H.M.S Gmbh Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
CA2785592A1 (en) * 2010-01-08 2011-07-14 Cavadis B.V. Determination of exosomel biomarkers for predicting cardiovascular events
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
JP5802614B2 (ja) * 2012-06-15 2015-10-28 富士フイルム株式会社 臨床情報表示装置および臨床情報表示装置の動作方法並びに臨床情報表示プログラム
JP5802615B2 (ja) * 2012-06-18 2015-10-28 富士フイルム株式会社 臨床情報表示装置および臨床情報表示装置の動作方法並びに臨床情報表示プログラム
US10415094B2 (en) 2016-10-06 2019-09-17 HelicalHelp LLC Risk stratification method for a patient having a polymorphism

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305142D0 (en) * 1993-03-12 1993-04-28 Medinnova Sf Method
AU2002349513B2 (en) * 2001-11-26 2007-10-18 Asubio Pharma Co., Ltd. Medicinal compositions for nasal absorption
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
DE60335387D1 (de) * 2002-07-16 2011-01-27 Woomera Therapeutics Inc Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
JP5320294B2 (ja) * 2006-10-26 2013-10-23 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化

Also Published As

Publication number Publication date
HK1135185A1 (en) 2010-05-28
WO2008067806A3 (de) 2008-09-25
US20100093012A1 (en) 2010-04-15
JP2010511877A (ja) 2010-04-15
JP2013210385A (ja) 2013-10-10
CN101583874B (zh) 2014-06-25
DE102006058266A1 (de) 2008-06-12
EP2100145A2 (de) 2009-09-16
EP2100145B1 (de) 2018-02-28
CN101583874A (zh) 2009-11-18
WO2008067806A2 (de) 2008-06-12

Similar Documents

Publication Publication Date Title
JP5320294B2 (ja) プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化
JP5584473B2 (ja) Ｎｙｈａｉ患者についての心機能不全の診断および危険性層化のためのナトリウム利尿ペプチドのインビトロ決定
JP5932924B2 (ja) 診断およびリスク層別化のためのｎｔ−プロｅｔ−１のインビトロ判定
CN101646945B (zh) 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层
JP5388858B2 (ja) ニューロフィジンを使用する心機能不全の診断および危険性の層化
CN101611314A (zh) 利用新颖标志物CT-proADM进行诊断和危险分层
JP2010526305A5 (enExample)
JP2010511877A5 (enExample)
JP2012502290A (ja) メタボリックシンドロームを有する患者におけるナトリウム利尿ペプチドおよびアディポネクチン
CN101600967B (zh) 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途
HK1135185B (en) Kit for diagnosis and risk stratification of cardiac insufficiency using neurophysin
HK1241025B (zh) 借助於利尿肽对nyha i级患者进行心功能不全的诊断和危险分层
HK1241025A1 (en) Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for nyha i patients
HK1140547B (en) Diagnosis and risk classification of acute coronary syndrome by means of ct-proet-1 in combination with nt-probnp
HK1137808B (en) Use of copertin or neurophysin ii in the manufacture of a kit for risk stratification for acute coronary syndrome
HK1140544A (en) Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for nyha i patients

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120330

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120417

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130701

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131008

R150 Certificate of patent or registration of utility model

Ref document number: 5388858

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees